Last reviewed · How we verify
prostaglandin of the clinician's choice
prostaglandin of the clinician's choice is a Small molecule drug developed by Sunnybrook Health Sciences Centre. It is currently in Phase 1 development. Also known as: Prostin, Cervidil.
At a glance
| Generic name | prostaglandin of the clinician's choice |
|---|---|
| Also known as | Prostin, Cervidil |
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prostaglandin of the clinician's choice CI brief — competitive landscape report
- prostaglandin of the clinician's choice updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI
Frequently asked questions about prostaglandin of the clinician's choice
What is prostaglandin of the clinician's choice?
prostaglandin of the clinician's choice is a Small molecule drug developed by Sunnybrook Health Sciences Centre.
Who makes prostaglandin of the clinician's choice?
prostaglandin of the clinician's choice is developed by Sunnybrook Health Sciences Centre (see full Sunnybrook Health Sciences Centre pipeline at /company/sunnybrook-health-sciences-centre).
Is prostaglandin of the clinician's choice also known as anything else?
prostaglandin of the clinician's choice is also known as Prostin, Cervidil.
What development phase is prostaglandin of the clinician's choice in?
prostaglandin of the clinician's choice is in Phase 1.
Related
- Manufacturer: Sunnybrook Health Sciences Centre — full pipeline
- Also known as: Prostin, Cervidil